Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation ...
Heart failure management includes the four pillars (quad therapy) in HFrEF and HFpEF, plus advances in heart transplantation and gene editing.
Everyday Health on MSN
Hypertrophic cardiomyopathy (HCM) and implantable devices: What to know about ICDs (and other options)
Two types of implantable cardioverter defibrillators can reduce the risk of sudden cardiac death with HCM. Pacemakers and implantable loop recorders also may be options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results